Chiasma is a clinical-stage biopharmaceutical company focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE^®) technology platform, Chiasma is developing octreotide capsules (conditionally trade named Mycapssa^®), for the maintenance therapy of adult patients with acromegaly in whom prior treatment with somatostatin analogs has been shown to be effective and tolerated.

The company resubmitted the NDA for Mycapssa for the maintenance therapy of adult patients with acromegaly in December 2019 and was notified of its acceptance in January 2020. The FDA assigned a Prescription Drug User-Fee Act (PDUFA) target action date of June 26, 2020, which is a six-month review.

Chiasma is committed to working with healthcare professionals in order to improve the lives of patients with acromegaly. Chiasma is headquartered in the United States with a wholly-owned subsidiary in Israel.